Validation of an MRI Rating Scale for Amyloid‐Related Imaging Abnormalities

Arianne Bechten; Mike P. Wattjes; Derk D. Purcell; Esther Sanchez Aliaga; Marita Daams; H. Robert Brashear; H. Michael Arrighi; Frederik Barkhof

doi:10.1111/jon.12422

journal article Jan 19, 2017

Validation of an MRI Rating Scale for Amyloid‐Related Imaging Abnormalities

Arianne Bechten Mike P. Wattjes Derk D. Purcell Esther Sanchez Aliaga Marita Daams H. Robert Brashear H. Michael Arrighi Frederik Barkhof

Journal of Neuroimaging Vol. 27 No. 3 pp. 318-325 · Wiley

View at Publisher Save 10.1111/jon.12422

Abstract

ABSTRACTINTRODUCTIONImmunotherapeutic agents against amyloid beta (Aβ) are associated with adverse events, including amyloid‐related imaging abnormalities with edema and effusion (ARIA‐E). Recently, a magnetic resonance imaging (MRI) rating scale was developed for ARIA‐E detection and classification. The aim of this study was to validate the use of this rating scale in a larger patient group with multiple raters.METHODSMRI scans of 75 patients (29 with known ARIA‐E and 46 control subjects) were analyzed by five neuroradiologists with different degrees of expertise, according to the ARIA‐E rating scale. For each patient, we included a baseline and a follow‐up fluid‐attenuated inversion recovery image. Interrater agreement was calculated using intraclass correlation coefficient (ICC).RESULTSOn average, 4.1% of the ARIA‐E cases were missed. We observed a high interrater agreement for scores of sulcal hyperintensity (SH; ICC = .915; 95% CI 85–95) and for the combined scores of the 2 ARIA‐E findings, parenchymal hyperintensity (PH) and SH (ICC = .878; 95% CI 79–93). A slightly lower agreement for PH (ICC = .678; 95% CI 51–81) was noted.CONCLUSIONThe ARIA‐E rating scale is a simple tool to evaluate the extent of ARIA‐E in patients recruited into Aβ‐lowering therapeutic trials. It shows high interrater agreement among raters with different degrees of expertise.

Topics

No keywords indexed for this article. Browse by subject →

References

17

[1]

10.1146/annurev.pharmtox.43.100901.140248

[2]

10.3233/jad-2011-110977

[3]

10.1017/s1041610211000913

[4]

10.1148/radiol.2531082262

[5]

10.1016/j.phrs.2003.12.028

[6]

10.1186/1742-4933-10-18

[7]

10.1371/journal.pone.0059735

[8]

10.1038/78682

[9]

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

Reisa A. Sperling, Clifford R. Jack, Sandra E. Black et al.

Alzheimer's & Dementia 10.1016/j.jalz.2011.05.2351

[10]

10.3174/ajnr.a3500

[11]

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

S. Salloway, R. Sperling, S. Gilman et al.

Neurology 10.1212/wnl.0b013e3181c67808

[12]

10.1016/j.jalz.2011.05.2353

[13]

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

Reisa Sperling, Stephen Salloway, David J Brooks et al.

The Lancet Neurology 10.1016/s1474-4422(12)70015-7

[14]

10.1161/01.str.32.6.1318

[15]

10.3174/ajnr.a3475

[16]

10.1097/wad.0b013e3181c53b00

[17]

10.1093/brain/awn261

Metrics

11

Citations

17

References

Details

Published: Jan 19, 2017
Vol/Issue: 27(3)
Pages: 318-325
License: View

Authors

A

Arianne Bechten

Image Analysis Centre, Department of Radiology and Nuclear Medicine VU University Medical Center Amsterdam the Netherlands

M

Mike P. Wattjes

Image Analysis Centre, Department of Radiology and Nuclear Medicine VU University Medical Center Amsterdam the Netherlands

D

Derk D. Purcell

Department of Radiology California Pacific Medical Center San Francisco CA; BioClinica Newark CA

E

Esther Sanchez Aliaga

Image Analysis Centre, Department of Radiology and Nuclear Medicine VU University Medical Center Amsterdam the Netherlands

M

Marita Daams

Department of Radiology and Nuclear Medicine and Department of Anatomy and Neurosciences, Neuroscience Campus Amsterdam VU University Medical Center Amsterdam the Netherlands

H

H. Robert Brashear

Janssen Alzheimer Immunotherapy Research and Development Fremont CA

H

H. Michael Arrighi

Janssen Alzheimer Immunotherapy Research and Development Fremont CA

F

Frederik Barkhof

Image Analysis Centre, Department of Radiology and Nuclear Medicine VU University Medical Center Amsterdam the Netherlands; Institutes of Neurology and Healthcare Engineering UCL London UK

Cite This Article

Arianne Bechten, Mike P. Wattjes, Derk D. Purcell, et al. (2017). Validation of an MRI Rating Scale for Amyloid‐Related Imaging Abnormalities. Journal of Neuroimaging, 27(3), 318-325. https://doi.org/10.1111/jon.12422

Validation of an MRI Rating Scale for Amyloid‐Related Imaging Abnormalities

You May Also Like